GLP-1 RAs like tirzepatide and semaglutide require special considerations for older adults with obesity and T2DM

The global prevalence of obesity and type 2 diabetes mellitus (T2DM) is continuously rising in older adults, affecting approximately 40% and 29% respectively. These conditions significantly impact quality of life, increase morbidity, and accelerate functional decline and cardiovascular disease. While glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are effective for T2DM and obesity management, their use in older adults requires special considerations due to increased comorbidity burden, polypharmacy, and specific risks like sarcopenia, which is often overlooked in weight loss strategies for this demographic.

This paper provides a comprehensive review of existing literature concerning the use of GLP-1 RAs in older adults diagnosed with type 2 diabetes mellitus and obesity. The authors synthesized evidence regarding the efficacy and safety profiles of various GLP-1 RAs, including tirzepatide, liraglutide, and semaglutide, specifically addressing the unique challenges and health considerations prevalent in this age group. The review focused on potential adverse effects, drug-drug interactions due to polypharmacy, and the critical risk of sarcopenia associated with significant weight loss in older adults.

GLP-1 RAs, such as tirzepatide, liraglutide, and semaglutide, promote weight loss by suppressing appetite, enhancing insulin secretion, and delaying gastric emptying. Large clinical trials have consistently demonstrated their efficacy in reducing glycated hemoglobin and body weight, alongside significant reductions in major renal and cardiovascular adverse events. However, the review highlighted that evidence specifically in older adults remains limited, necessitating a cautious approach. Key considerations include the risk of sarcopenia, where weight loss might disproportionately affect muscle mass, and the complexities of polypharmacy, which can increase the likelihood of adverse drug interactions and side effects. Despite these challenges, the overall conclusion is positive:

GLP-1 RAs represent a valuable and promising treatment option for older adults with T2DM and obesity when managed with appropriate clinical oversight and individualized care plans. This underscores the need for careful patient selection and monitoring.